NSD2-IN-6

NSD2-IN-6 (compound NSD2i) shows a substantial reduction in H3K36me2 domains in NPPO-1NE organoids^[1].
NSD2-IN-6 results a substantial shift from cluster 2 and 3 states towards the cluster 1 state and enrichment of canonical AR target expression in NPPO-1NE organoids^[1].
NSD2-IN-6 has little or no effect on AR expression in non-neuroendocrine organoids with combined Enzalutamide ^[1].
NSD2-IN-6 (1 µM, 17 days) increases sensitivity to enzalutamide in NPPO-1NE, NPPO-2, NPPO-4 and NPPO-6 organoids with EC₅₀ values of 0.34, 2.7, 1.6 and 20 µM respectively^[1].
NSD2-IN-6 (0.3-10 µM, 26 days ) not affect on NSD2 knockout NPPO-1 and NPPO-2 organoids, has a slight effect on NSD2 knockout MSKPCa10^[1].
NSD2-IN-6 (10 µM, 21 days) reduces H3K36me2 expression and modest upregulates H3K27me3 in MSKPCa10, MSKPCa14, WCM154, WCM1262 and MSKPCa2 human CRPC organoid lines, loss the lineage marker CD56 and upregulates AR in WCM1262 human CRPC organoid lines, results a reduction in organoid size and immunostaining for cleaved caspase 3 in MSKPCa2 organoids^[1].
NSD2-IN-6 (0.3-10 µM, 21 days) lead a decreasing cell viability after enzalutamide treatment, a high Bliss synergy score and a concentration-dependent induction of apoptosis in MSKPCa10, MSKPCa14, WCM154, WCM1262 and MSKPCa2 human CRPC organoid lines when combinate with Enzalutamide ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.